Corpseed

Drug Import Shelf-Life Rules 2026: What Has Changed Under Rule 31?

Department: Department of Health and Family WelfareAuthority: CDSCOPublish: Applicable: 16-10-2026Product Quality ComplianceMedical Device and Pharmaceutical

Quick note

Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.

Schedule a Call Back

IN +91

Businesses we've worked with on drug licence

Clients include Cure and Care Wellness, 1008 Digital Health, Nfilade Security Solutions, Evoq Technologies, Kantika Import Export and Trading, Rock Well Industries, Abhay Healthtech, Hind Svasthya Healthcare, Pridus Global Pharma, Arka Brenstech, Believe Cosmetics, Imedicndr Healthcare (12 of 40+ served since 2018).

A few more clients we've served in this industry
Clients include
Cure and Care Wellness · 1008 Digital Health · Nfilade Security Solutions · Evoq Technologies · Kantika Import Export and Trading · Rock Well Industries · Abhay Healthtech · Hind Svasthya Healthcare · Pridus Global Pharma · Arka Brenstech · Believe Cosmetics · Imedicndr Healthcare · Katre Enterprises · Soapsquare Healthcare · Xsourcee
See our drug licence service →

Summary

A medicine may still be within its expiry date but fail to meet India's import requirements. What matters is how much shelf life remains when the drug is imported.

The Ministry of Health and Family Welfare has revised the drug import shelf-life rules in India through notification G.S.R. 951(E), introducing the Drugs (Thirteenth Amendment) Rules, 2026. Under the amended Rule 31, imported drugs must generally have at least one year of remaining shelf life. Biological drugs and radiopharmaceuticals have a separate provision under which 60% of their labelled shelf life may be allowed.

The change is important for pharmaceutical importers, overseas manufacturers supplying the Indian market and businesses managing medicine imports. It affects how they assess product expiry dates, plan shipments and comply with applicable CDSCO drug import requirements.

For businesses reviewing pharmaceutical import compliance in India, the key question is which shelf-life rule applies to their medicine before it enters the country.

Notification at a Glance

The government issued the final amendment after considering feedback received on the draft rules published in June 2026. The main details are given below.

Particular Notification details
Notification Drugs (Thirteenth Amendment) Rules, 2026
Reference number G.S.R. 951(E)
Issuing ministry Ministry of Health and Family Welfare
Notification date 16 October 2026
Date printed in the Gazette 28 October 2026
e-Gazette publication listing 29 October 2026
Commencement Date of publication in the Official Gazette
Law amended Drugs Rules, 1945, Rule 31 (second proviso)
General shelf-life condition At least one year remaining at the date of import
Special categories Biological drugs and radiopharmaceuticals: 60% of labelled shelf life may be allowed
Main affected activity Import of drugs into India

The Gazette issue bears the date 28 October 2026, while the official e-Gazette listing records publication on 29 October 2026. The rules expressly take effect from the date of Gazette publication.

The Regulatory Framework for Drug Imports in India

Drug imports into India are regulated under the Drugs and Cosmetics Act, 1940, and the applicable Drugs Rules, 1945.

These laws contain provisions concerning drug quality, manufacturing standards, import permissions, packaging, labelling and other conditions intended to protect public health.

The Central Drugs Standard Control Organization (CDSCO), headed by the Drugs Controller General (India), performs important central regulatory functions relating to drugs imported into the country.

Businesses planning a CDSCO drug import licence application should review the product's shelf life alongside any other approvals that apply to the proposed import.

What Does Rule 31 of the Drugs Rules, 1945 Cover?

Rule 31 is titled Standard for certain imported drugs.

It deals with the standards of strength, quality and purity that imported drugs must satisfy. It also includes provisions concerning the remaining shelf life of drugs when they are imported.

A drug's shelf life is the period during which it is expected to remain suitable for use under its approved storage conditions.

The 2026 notification changes the second proviso to Rule 31, which concerns the minimum remaining shelf life for imported drugs.

Other requirements relating to drug quality, safety, packaging and applicable import permissions continue to operate under the relevant laws.

What Was the Earlier Shelf-Life Requirement?

Before the latest amendment, the general rule required imported drugs to have at least 60% of their shelf life remaining on the date of import.

This meant the permitted remaining period depended on the total shelf life assigned to the product.

Under the revised rule, the general requirement is no longer based on that percentage. Instead, the licensing authority must apply a fixed one-year residual shelf-life condition, subject to the relevant special provisions.

What Has Changed Under the Drugs (Thirteenth Amendment) Rules, 2026?

The biggest change is the replacement of the earlier general 60% requirement with a one-year minimum remaining shelf life for imported drugs.

The amendment also expressly addresses biological drugs and radiopharmaceuticals separately.

The distinction matters because medicines do not all have the same labelled shelf life. Some remain suitable for use for several years, while others have much shorter approved periods.

Earlier vs New Drug Import Shelf-Life Requirements

Drug category or issue Earlier general position Position under G.S.R. 951(E) What importers should check
General imported drugs Generally at least 60% of shelf life remaining At least one year of residual shelf life Labelled expiry date and date of import
Biological drugs Earlier general percentage-based rule 60% of labelled shelf life may be allowed Product classification and the applicable licensing decision
Radiopharmaceuticals Earlier general percentage-based rule 60% of labelled shelf life may be allowed Product classification and the applicable licensing decision
Assessment date Date of import Date of import Whether shipment timing changes the remaining period

The amendment should not be understood as a relaxation for every imported medicine.

For drugs with a relatively long total shelf life, a fixed one-year requirement may be less restrictive than the earlier 60% condition. For products with a short total shelf life, it may be more restrictive.

Importers therefore need to look at the actual product and its remaining shelf life rather than assume that the new rule will affect every shipment in the same way.

Why Did the Government Change the Rule?

The Ministry of Health and Family Welfare explained the reasons for the proposed amendment in its announcement dated 26 June 2026.

The government's stated objectives included improving pharmaceutical supply-chain efficiency, reducing avoidable medicine wastage and making inventory management easier.

The earlier percentage-based requirement could restrict the import of certain medicines even when they still had a substantial period before expiry.

The proposed one-year requirement was intended to provide a more practical approach while continuing to ensure that medicines entering India have sufficient usable shelf life.

The government also made clear that the proposal was not intended to change the existing requirements concerning drug quality, safety or efficacy.

The final amendment was subsequently notified through G.S.R. 951(E).

Minimum Residual Shelf-Life Requirements for Imported Drugs in India

Under the revised Rule 31, the licensing authority shall not allow the import of a drug having less than one year of residual shelf life on the date of import, subject to the applicable provisions.

This makes expiry-date information an important part of pharmaceutical import planning.

The minimum shelf life for imported medicines in India must therefore be assessed using the product's remaining period, not simply whether the batch is still within its expiry date.

What Is Residual Shelf Life?

Residual shelf life is the period remaining before a medicine reaches its labelled expiry date.

It should not be confused with the drug's total shelf life.

Total shelf life refers to the complete approved period for which the medicine is assigned a shelf life.

Residual shelf life refers to the unused portion of that period at a particular point in time.

A medicine that has not expired does not automatically satisfy the revised import requirement. Its remaining shelf life must still meet the applicable condition.

How Does the One-Year Requirement Apply?

For drugs covered by the general requirement, at least one year of shelf life must remain on the date of import.

The wording is important. The rule restricts imports where the remaining period is less than one year.

The notification does not make the date of placing a purchase order or receiving confirmation from the overseas manufacturer the deciding point.

Importers should therefore review the product's expiry information alongside the expected import date.

A shipment planned well in advance may require another shelf-life check if its arrival schedule changes.

Why Should Importers Check Expiry Dates Before Shipment?

The remaining shelf life continues to decrease while a medicine is being stored, transported or awaiting import.

A product that appears suitable when an order is placed may have a shorter remaining period by the time it reaches India.

Importers should consider this when finalising shipment schedules, especially where the available shelf life is close to the applicable threshold.

Checking the batch and expiry information before shipment can help businesses identify potential problems before goods are dispatched.

This is a practical compliance measure, not a new government filing procedure created by the amendment.

Special Shelf-Life Provisions for Biological Drugs and Radiopharmaceuticals

The new one-year requirement is not the only shelf-life condition mentioned in the notification.

The government has retained a separate percentage-based approach for biological drugs and radiopharmaceuticals.

The amended proviso states that 60% of the labelled shelf life may be allowed for these categories.

Shelf-Life Requirement for Biological Drugs

Biological drugs are medicines associated with biological sources or processes. Certain vaccines and other specialised medicinal products fall within biological drug regulation, depending on their classification.

Such products may have specific stability, storage and handling requirements.

Under the amended Rule 31, the licensing authority may allow 60% of the labelled shelf life in the case of biological drugs.

This provision differs from the general one-year requirement because it refers to a percentage of the product's labelled shelf life.

Importers should verify the actual regulatory classification of the medicine before deciding which condition applies.

A product should not be treated as a biological drug merely because it requires special storage or temperature control.

For businesses checking biological drugs import requirements in India, accurate product classification is essential before applying the separate percentage-based condition.

Shelf-Life Requirement for Radiopharmaceuticals

Radiopharmaceuticals are medicinal products containing radioactive substances used for medical purposes, including certain diagnostic and therapeutic applications.

These products can have specialised shelf-life and handling characteristics.

The amended Rule 31 separately provides that 60% of their labelled shelf life may be allowed.

Businesses importing radiopharmaceuticals should therefore assess the relevant product information and applicable regulatory conditions before arranging imports.

Radiopharmaceutical import compliance also involves checking other applicable permissions; meeting the stated shelf-life condition is not a substitute for those approvals.

Does the 60% Provision Guarantee Import Approval?

No.

The notification uses the expression may be allowed. It does not state that every biological drug or radiopharmaceutical with a particular remaining shelf-life percentage must automatically receive import permission.

The licensing authority must still act under the applicable legal framework.

Businesses should also remember that satisfying a shelf-life condition does not remove other import, safety, quality or product approval requirements.

How Will the Revised Rule 31 Affect Drug Import Licence Approvals?

The revised shelf-life condition is relevant to the licensing authority's decision to permit imported drugs.

This does not mean that every existing drug importer must apply for a completely new import licence.

The amendment concerns an import condition, not the creation of a new licensing category.

Role of CDSCO in Pharmaceutical Imports

CDSCO is responsible for important central regulatory functions involving the import of drugs into India.

Importers may require the applicable licences, permissions or other approvals depending on the type of pharmaceutical product and the purpose of import.

The revised Rule 31 becomes relevant when assessing whether a drug satisfies the prescribed shelf-life condition at import.

Businesses seeking CDSCO drug import licence assistance should ensure that the proposed shipment is reviewed against all applicable requirements, not only its expiry date.

A drug import licence consultant in India may help applicants understand the relevant licensing steps and documentation, although hiring a consultant is not a legal requirement.

Can a Drug Import Be Refused Because of Insufficient Shelf Life?

Yes. The amended rule prevents the licensing authority from allowing imports that do not meet the applicable shelf-life condition, subject to the legal provisions governing any permitted exceptions.

A product being within its labelled expiry date is not enough by itself.

However, businesses should distinguish refusal of permission for a particular import from suspension or cancellation of an existing licence.

The notification does not introduce an automatic licence-cancellation penalty for failing to satisfy the revised shelf-life threshold.

Are There Any Exceptional Cases?

The earlier CDSCO-published text of Rule 31 includes an additional proviso allowing the licensing authority, in exceptional cases, to consider imports with shorter remaining shelf life.

That proviso refers to reasons being recorded in writing and the drug remaining within its declared expiry date.

The 2026 notification expressly substitutes the second proviso. It does not expressly replace the additional exceptional-cases proviso.

However, businesses should not assume that exceptional permission will be available in every situation or that the earlier procedure can be followed without change.

The application of this provision alongside the revised one-year threshold should be confirmed with CDSCO or the relevant licensing authority before relying on it.

Any request concerning CDSCO import approval for drugs with shorter shelf life should be assessed individually; older guidance referring to the previous 60% rule should not be assumed to describe the current procedure.

Does the Amendment Introduce New Fees or Registration Documents?

Notification G.S.R. 951(E) does not prescribe a separate registration fee, a new shelf-life certificate or an additional application form.

Existing fees, documents and licensing procedures may still apply under the relevant drug import rules.

Importers should determine the requirements applicable to their specific product and regulatory activity rather than assume that the shelf-life amendment creates an entirely new approval process.

Impact of the New Shelf-Life Rules on Pharmaceutical Importers

The amendment is relevant to businesses that import medicines into India, but its practical impact will depend on the type of product and its remaining shelf life.

For importers comparing pharmaceutical import compliance services, the useful starting point is an assessment of the relevant drug category, shelf-life condition and existing CDSCO permissions.

Impact on Pharmaceutical Importers

Importers of medicines covered by the general rule now need to assess whether the products will have at least one year of shelf life remaining when imported.

The change may affect which batches they choose to purchase from overseas suppliers.

It may also influence discussions about expiry dates, delivery schedules and available stock.

Where an importer previously relied on the general 60% threshold, internal compliance checks may need to be updated.

Impact on Overseas Pharmaceutical Manufacturers

Overseas manufacturers supplying medicines to India may receive more requests for accurate batch and expiry information.

Although the amended provision is an import requirement, manufacturers may need to coordinate with Indian customers to ensure that the supplied products can meet the applicable condition.

This may affect the choice of batches and logistics planning for India.

Impact on Importers of Biological Drugs and Radiopharmaceuticals

Importers of biological drugs or radiopharmaceuticals would be especially interested in the 60% provision.

These importers should review the labelled shelf life, regulatory classification and any additional product-specific conditions.

The amendment does not remove separate requirements relating to quality, storage or handling.

Impact on Medicine Supply Chains

The new rules will affect certain business decisions:

  • Selection of suppliers: The decision makers of imports may look at whether foreign suppliers can offer batches with adequate shelf life left.
  • Shipping arrangements: Shipping time must be kept in mind because it takes time from dispatching to importing.
  • Inventory management: The business may have to reconsider which batches are appropriate for the Indian market.
  • Coordination of regulations: The departments of imports and compliance will have to review the internal process in light of the new Rule 31.

These are practical business considerations. The notification does not establish a separate mandatory inventory-management system.

How Can Importers Check the Remaining Shelf Life of Imported Drugs?

The most useful time to review shelf life is before shipment.

A business may already have the required import permissions, but the actual product or batch must still meet the applicable import conditions.

Importers can use the following information when reviewing a proposed shipment.

Information to review Why it matters
Name and regulatory category of the drug Helps identify the applicable general or special shelf-life provision
Labelled expiry date Shows when the product's stated shelf life ends
Labelled total shelf life Relevant to a percentage-based shelf-life assessment
Batch-specific product information Helps connect the stated expiry date with the batch being imported
Expected date of import Determines the remaining shelf life for the regulatory check
Applicable licences or import permissions Helps identify separate CDSCO requirements that still apply

This table is a practical review guide. It is not a new statutory document checklist introduced by G.S.R. 951(E).

Check the Product's Actual Expiry Information

Importers should use information that relates to the product and batch intended for import.

Where different documents contain inconsistent expiry details, those differences should be clarified with the supplier before proceeding.

Confirm the Applicable Drug Category

The same shelf-life approach should not automatically be used for every type of imported drug.

Businesses should establish whether the product falls under the general one-year condition or the separate provision for biological drugs and radiopharmaceuticals.

Review the Expected Import Date

Importers should consider whether the remaining shelf life will satisfy the applicable condition on the date of import.

If shipment arrangements change, the assessment may need to be updated.

Keep Relevant Information Available

Manufacturer-provided product information, relevant labels and applicable regulatory records may help businesses support their internal checks.

The exact documents legally required for a particular import depend on the applicable regulatory framework.

What Should Pharmaceutical Importers Do Next?

Businesses importing medicines into India should review the new Rule 31 requirements before finalising relevant shipments.

The following checklist can help importers identify matters that deserve attention.

Drug Import Compliance Checklist Under the 2026 Amendment

1. Review the amended Rule 31

Be aware of the general one-year period as well as specific periods for biological products and radiopharmaceuticals.

2. Determine the drug type

Determine which condition of regulation is applicable to the imported drug.

3. Check product expiry date

Analyze the remaining shelf-life of the batch being imported and resolve any contradictions in the information received from the manufacturer.

4. Consider the shipping and import dates

Determine whether any possible shipping changes will impact the remaining shelf-life of the product at the time of import.

5. Review existing import compliance procedures

Update internal references to the earlier general 60% requirement where necessary.

6. Check other applicable approvals

Make sure the business continues to meet the relevant CDSCO licensing, quality and import requirements.

7. Seek regulatory clarification where required

In case of doubt concerning a specific item or shipment, seek the advice of the relevant authority or pharmaceutical regulation expert.

These steps are recommended business practices. The legally binding requirements remain those provided under the applicable laws and rules.

How Corpseed Can Help with Drug Import Compliance in India

Importing medicines into India can involve several regulatory checks, from identifying the applicable permissions to preparing documentation and understanding the conditions attached to a particular product.

A business may need help determining which CDSCO requirements apply before it begins the import process. Corpseed provides assistance through its CDSCO registration services and related pharmaceutical regulatory services.

Businesses looking for CDSCO registration consultancy, drug import licence application support or related pharmaceutical regulatory compliance services should first establish which service matches their product and licensing requirements. Depending on the required service and agreed scope, support may include the following.

1. CDSCO Registration and Licensing Guidance

Assistance in understanding the registration, licensing and approval requirements relevant to the proposed pharmaceutical business activity.

2. Regulatory Documentation Support

Guidance on preparing and organising documents required for applicable CDSCO registration or licensing processes.

3. Pharmaceutical Import Compliance Guidance

Support in identifying regulatory provisions relevant to pharmaceutical imports and the information businesses may need to review.

4. Application and Regulatory Coordination

Assistance with applicable regulatory applications, documentation and related coordination, depending on the service requirements.

5. Understanding New Regulatory Requirements

Guidance on how changes such as the revised Rule 31 may affect a business's compliance planning.

Businesses should confirm whether product-specific shelf-life review or exceptional import permission assistance falls within the service being requested.

Need assistance with CDSCO registration or pharmaceutical import compliance?

Speak with Corpseed to understand the regulatory approvals, documentation and compliance requirements relevant to your pharmaceutical business in India.

Key Takeaways

The Drugs (Thirteenth Amendment) Rules, 2026 have changed the general residual shelf-life requirement for imported drugs in India.

Under the amended Rule 31, imported drugs must generally have at least one year of remaining shelf life on the date of import.

Biological drugs and radiopharmaceuticals are addressed separately, with a provision under which 60% of their labelled shelf life may be allowed.

The amendment does not create a new drug import licence category or remove other applicable pharmaceutical safety, quality and licensing requirements.

Importers should review their product information, shipment planning and relevant regulatory obligations before proceeding with imports.

Document Preview

Embedded reference document

Fullscreen ↗

Related

Explore more updates from the same department.

Call